Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A meta-analysis of studies including 1,066 patients.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Acta ophthalmologica

• Publication date

  1999-08-01

• Fields of study

  Medicine, Physics

• Identifiers
  DOI 10.1034/J.1600-0420.1999.770411.XPMID 10463412
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Posterior uveal melanoma. The Swedish perspective.

  2009cited by this paper
• Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma. The Swedish experience.

  2009cited by this paper
• Radiation therapy for choroidal melanoma.

  1997cited by this paper
• Survival of patients and metastatic and local recurrent tumor growth in malignant melanoma of the uvea after ruthenium plaque radiotherapy.

  1993cited by this paper
• Rates of local control, metastasis, and overall survival in patients with posterior uveal melanomas treated with ruthenium-106 plaques.

  1993cited by this paper
• A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988.

  1992cited by this paper
• Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years' experience.

  1986cited by this paper

• GEC-ESTRO survey of 106Ru eye applicator practice for ocular melanoma - physicist survey.

  2024cites this paper
• Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy

  2022cites this paper
• Personalized treatment planning in eye brachytherapy for ocular melanoma: Dosimetric analysis on ophthalmic structure at risk.

  2020cites this paper
• NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019.

  2020cites this paper
• Hypofractionated stereotactic photon radiotherapy of choroidal melanoma: 20-year experience

  2020cites this paper
• Surface dose rate from a flat 106Ru/106Rh episcleral plaque measured with a planar windowless extrapolation chamber and un-laminated EBT3 film

  2019cites this paper
• AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of Task Group 221.

  2019cites this paper
• A convex windowless extrapolation chamber to measure surface dose rate from 106 Ru/106 Rh episcleral plaques.

  2019cites this paper
• Prognostic value of genome-wide DNA methylation patterns in noncoding miRNAs and lncRNAs in uveal melanomas

  2019cites this paper
• Principles of Cancer Epidemiology

  2019cites this paper
• 15 years of 106Ru eye plaque dosimetry at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center using radiochromic film in a Solid Water phantom

  2018cites this paper
• Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions

  2018cites this paper
• Windowless extrapolation chamber measurement of surface dose rate from a 90 Sr/ 90 Y ophthalmic applicator

  2018cites this paper
• Nomogram for predicting radiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma

  2017cites this paper
• Uveal Melanoma Regression after Brachytherapy: Relationship with Chromosome 3 Monosomy Status

  2016cites this paper
• [Prognostic factors for uveal melanoma].

  2015cites this paper
• Separation and purification of 106Ru from effluent streams of ion-exchange cycle used for Pu purification in PUREX process

  2014cites this paper
• Assessment of ocular beta radiation dose distribution due to 106Ru/106Rh brachytherapy applicators using MCNPX Monte Carlo code

  2014cites this paper
• Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma.

  2014cites this paper
• Principles of clinical epidemiology

  2014cites this paper
• Prognosis of choroidal melanoma and the result of ruthenium brachytherapy combined with transpupillary thermotherapy in Korean patients

  2013cites this paper
• Brachytherapy and endoresection for choroidal melanoma: a cohort study

  2013cites this paper
• Uveal melanoma in England: trends over time and geographical variation

  2012cites this paper
• Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.

  2012cites this paper
• Ruthenium-106 brachytherapy.

  2012cites this paper
• Relative survival of patients with uveal melanoma managed in a single center

  2012cites this paper
• The comparison of ruthenium brachytherapy and simultaneous transpupillary thermotherapy of choroidal melanoma with brachytherapy alone.

  2012cites this paper
• Macrophages in Regressed and Progressed Uveal Melanoma

  2011cites this paper
• Relative Contribution of Cell Proliferation and Microvascularity to Metastasis in Malignant Uveal Melanoma

  2011cites this paper
• Uveal melanoma: trends in incidence, treatment, and survival.

  2011cites this paper
• Basic principles Principles of clinical epidemiology

  2011cites this paper
• Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas

  2009cites this paper
• Dosimetric comparison of 106Ru and 125I plaques for treatment of shallow (<or=5 mm) choroidal melanoma lesions.

  2008cites this paper
• Survival from Uveal Melanoma in England and Wales 1986 to 2001

  2007cites this paper
• Evidence-based practice in acute ophthalmology

  2007cites this paper
• RUTHENIUM-106 BRACHYTHERAPY FOR UVEAL MELANOMAS – PRELIMINARY RESULTS : A SINGLE INSTITUTIONAL EXPERIENCE *

  2007cites this paper
• Braquiterapia com rutênio-106 em melanomas uveais - resultados preliminares: experiência uni-institucional

  2007cites this paper
• CHAPTER 1 – Principles of clinical epidemiology

  2007cites this paper
• Current management of uveal melanoma

  2007cites this paper
• Uveal and Conjunctival Malignant Melanoma in Denmark 1943–97: Observed and Relative Survival of Patients Followed Through 2002

  2006cites this paper
• Iodine Brachytherapy for Large Uveal Melanomas

  2006cites this paper
• Ru106 brachytherapy for management of choroidal melanoma: do we need to adjust total dose according to the new NIST calibration measurement?

  2005cites this paper
• Clinical quality assurance for 106Ru ophthalmic applicators.

  2005cites this paper
• Uveal melanoma: epidemiologic aspects.

  2005cites this paper
• 18 Years’ experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma

  2005cites this paper
• Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.

  2005cites this paper
• Uveal melanoma : Epidemiological and clinical aspects

  2005cites this paper
• On the Actual State of Industrial Quality Assurance Procedures with Regard to 106Ru Ophthalmic Plaques

  2004cites this paper
• Tumour-lysis-related elevation of intraocular pressure following high-dose-rate brachytherapy for choroidal melanoma

  2004cites this paper
• Ocular melanoma.

  2003cites this paper
• Uveal melanoma survival in Sweden from 1960 to 1998.

  2003cites this paper
• 30 Uveal Melanoma

  2003cites this paper
• Therapy of Uveal Melanoma: Methods and Risk Factors Associated with Treatment

  2003cites this paper
• Survival rates with uveal melanoma in the United States: 1973-1997.

  2003cites this paper
• Clinical Overview of Uveal Melanoma

  2003cites this paper
• Does escalation of the apical dose change treatment outcome in beta-radiation of posterior choroidal melanomas with 106Ru plaques?

  2002cites this paper
• Thermotherapy in the management of choroidal melanoma.

  2002cites this paper
• Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy.

  2002cites this paper
• Cellular radiosensitivity of primary and metastatic human uveal melanoma cell lines.

  2002cites this paper
• [Therapy relevant weak sites in industrial quality assurance of 106Ru eye plaques].

  2001cites this paper
• Prognostic indicators in choroidal and ciliary body melanoma

  2001cites this paper
• The measurement of three dimensional dose distribution of a ruthenium‐106 ophthalmological applicator using magnetic resonance imaging of BANG polymer gels

  2001cites this paper
• Therapierelevante Schwachstellen bei der industriellen Qualitätssicherung von 106Ru-Augenapplikatoren

  2001cites this paper
• The measurement of three dimensional dose distribution of a ruthenium-106 ophthalmological applicator using magnetic resonance imaging of BANG polymer gels

  2000cites this paper
• Clinical Ophthalmology Dovepress

  year unknowncites this paper